Fontan-Sprechstunde

NCT ID: NCT05563376

Last Updated: 2022-10-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-01

Study Completion Date

2041-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

After successful Fontan surgery, the risk of mortality in childhood is only low. Unfortunately, some of the patients suffer from Fontan-typical long-term complications in the long-term course, whereby protein loss neuropathy must be mentioned in particular, which is described in the literature with an incidence of 3-14% (1, 2) and still has a 5-year risk of death of 6-12% today (2, 3). Protein loss tereopathy leads to loss of protein in the intestine and subsequently to diarrhea and edema. Other problems concern the liver, which can develop cirrhosis due to chronic congestion (4-6). Cardiac can lead to heart failure and arrhythmias.

The registry study described in this protocol is intended to identify factors that influence the treatment outcome of patients in the Fontan circulation in the long term through systematic prospective documentation of the data from our standardized and guideline-oriented treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In particular, the following points will be scientifically analyzed:

1. The development of lymphatic drainage disorders (7-9)
2. The cellular changes of the immunological system and metabolome (10) In addition to the clinical routine, weight-adapted EDTA blood for the isolation of peripheral blood mononuclear cells (PBMCs) for the scientific investigation of immunological changes and serum for the analysis of the metabolome will be examined at three times (Figure 1: Times 2, 4, 7) as part of a routine blood sample (10).
3. The recording and treatment of psychological, social and developmental abnormalities with the help of standardized questionnaires.
4. The evaluation of special sonography examinations of the liver and kidney in the long-term course, as well as their treatment.
5. The assessment of the hemodynamic peculiarities and the classification with regard to Cardiac function in the long-term course of patients with Fontan circulation.
6. The assessment of various laboratory parameters as risk parameters for the development of complications.
7. The recording of cardiopulmonary performance in the long-term course and its ability to be influenced by education regarding sporting activity and the handing over of an individualized training plan.
8. The influence of physical activity on possible complications of Fontan circulation.
9. The influence of early psychological, nutritional, or social intervention in the event of abnormalities on later complications of Fontan circulation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Univentricular Heart

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TCPC completed

All patients after TCPC completion

Group Type OTHER

Univentricular Hearts

Intervention Type DIAGNOSTIC_TEST

Prevention when factors are recognized

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Univentricular Hearts

Prevention when factors are recognized

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* congenital heart defect of the univentricular type that has led to Fontan circulation
Minimum Eligible Age

6 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Erlangen-Nürnberg Medical School

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sven Dittrich, Prof.

Role: STUDY_CHAIR

Universitätsklinikum Erlangen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universitätsklinikum

Erlangen, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Isabelle Schöffl, PD

Role: CONTACT

09131 85 33750

Sven Dittrich, Prof.

Role: CONTACT

09131 85 33750

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sven Dittrich, Prof.

Role: primary

09131 85 33750

Isabelle Schöffl, PD

Role: backup

09131 85 33750

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

21-195_1-B

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CTO-PCI in Heart Failure Patients
NCT05632653 NOT_YET_RECRUITING NA